lefitolimod

Lefitolimod is a synthetic oligonucleotide and investigational immunotherapy that acts as a toll-like receptor 9 (TLR9) agonist. It belongs to the family of double-stem loop immunomodulators (dSLIM). Lefitolimod binds to and activates TLR9 on plasmacytoid dendritic cells and B cells, triggering innate immune responses including secretion of type I interferons such as IFN-alpha. This activation leads to downstream stimulation of natural killer cells, cytotoxic T lymphocytes, monocytes, and B cells. The drug has been studied as a latency-reversing agent in HIV infection—aiming to reactivate latent virus reservoirs—and as an immunotherapeutic agent in various cancers including small cell lung cancer and colorectal cancer. Lefitolimod is being developed by Mologen for these indications[1][2][5][7].

Other names

TLR9 agonist MGN1703TLR-9 agonist MGN1703TLR 9 agonist MGN1703double-stem loop immunomodulator (dSLIM)